Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 07

4P - Immune checkpoint inhibitors in adrenocortical carcinoma: A meta-analysis

Date

10 Sep 2022

Session

Poster session 07

Topics

Clinical Research;  Immunotherapy

Tumour Site

Adrenal Carcinoma

Presenters

Obada Ababneh

Citation

Annals of Oncology (2022) 33 (suppl_7): S1-S3. 10.1016/annonc/annonc

Authors

O. Ababneh1, S. Al-Horani1, A. Ghazou1, M. Alawajneh1, B. Shehadeh1, O. Kadoumi1, S. Alhaj Mohammad1, A. Bani-Hani1, N. Alrabadi2

Author affiliations

  • 1 Medicine, Jordan University of Science and Technology, 22110 - Irbid/JO
  • 2 Pharmacology, Jordan University of Science and Technology, 22110 - Irbid/JO

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4P

Background

Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with few treatment options. The use of immune checkpoint inhibitors (ICI) has revolutionized the way many malignancies are treated. However, its role in ACC is still unclear. Thus, we performed a meta-analysis to summarize the efficacy of ICI in patients with ACC.

Methods

A systematic review was performed for studies published in PubMed, Scopus, CENTRAL, ASCO, and ESMO meeting abstracts. Studies that reported overall survival (OS), progression-free survival (PFS), or objective response rate (ORR) and were with at least 5 patients were included in the meta-analysis. We estimated the proportions for ORR, disease control rate (DCR), PFS, OS and adverse events using the fixed-effect model.

Results

We included 9 studies with a total number of 168 patients. Six studies used anti-PD(L)-1 monotherapy (n=113), 2 studies used anti-PD(L)-1 and anti-CTLA4 combination therapy (n=24) and 2 studies used anti-PD1 combined with chemotherapy (n=31). Patients’ median age across studies ranged from 43 to 62 with 60.6% being females. The pooled ORR was 10% (95% CI: 4.6%-15.6%, I2 = 0%) for anti-PD(L)-1 monotherapy, 8.7% (95% CI: 0%-20%, I2 = 0%) for anti-PD(L)-1 and anti-CTLA4 combination therapy, and 9.9% (95%CI: 0%-20.1%, I2 = 0%). For the pooled DCR, it was 45.4% (95% CI: 36.3%-54.4%, I2 = 0%) for anti-PD(L)-1 monotherapy, 54.9% (95% CI: 34.4%-75.5%, I2 = 0%) for anti-PD(L)-1 and anti-CTLA4 combination therapy, and 70.5% (95%CI: 26.5%-100%, I2 = 90.3%) for anti-PD1 combined with chemotherapy. The median PFS was 1.88 months (95%CI: 1.08-2.69, I2 = 0%) for anti-PD(L)-1 monotherapy. The was not enough data regarding PFS and OS for further analyses. Pooled all grades adverse events were 24.0% (95%CI: 12.9%-35.2%, I2 = 92.41%) for anti-PD(L)-1 monotherapy and 39.1% (95%CI: 9%-69.2%, I2 = 94.7%) for anti-PD1 combined with chemotherapy. Grade 3/4 adverse events were 17% (95%CI: 10.1%-24.%, I2 = 0%) for anti-PD(L)-1 monotherapy and 11.8% (95%CI: 5.5%-18.1% , I2 = 0%) for anti-PD1 combined with chemotherapy.

Conclusions

Combination therapy showed a similar ORR and safety profile but higher DCR compared to single-agent anti-PD(L)-1. Survival data were scarce and should be reported more in future combination-based ICI trials.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.